



## FDA clears Lynparza for prostate cancer treatment

The National Desk

June 7, 2023

WASHINGTON (TND) — The Food and Drug Administration cleared a new cancer-fighting drug called Lynparza for prostate cancer treatment.

Senior Fellow at the Cato Institute Dr. Jeffrey Singer joined The National Desk’s Jan Jeffcoat to discuss the issue.

“Abiraterone is a drug that was approved by the FDA to treat very advanced and very difficult cases of prostate cancer,” he said. “Researchers recently found that by adding the steroid prednisone but it increases effectiveness by 76% and the combination is called Lynparza.”

The approval was based on their findings in the PROpel trial that enrolled 796 patients with metastatic castration-resistant prostate cancer.

The study concluded that there was a significant improvement in the patients who received Lynparza with abiraterone.

“Lynparza has been approved by the FDA to treat breast cancer, certain kinds of breast cancer, but now it's been approved to treat prostate cancer,” Singer said. “Interestingly, and this is not an unusual story, Lynparza was approved to treat prostate cancer months ago in Europe and other countries.”